FDA approves Panzyga for chronic inflammatory demyelinating polyneuropathy
The U.S. Food and Drug Administration approved the supplemental Biologics License Application for Immune Globulin Intravenous (Human) – ifas 10% Liquid Preparation (Panzyga; Pfizer) to treat adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP), according to a press release. This is the only FDA-approved intravenous immunoglobulin with 2 maintenance dosing options for CIDP.
CIDP is a rare neurological disease of the peripheral nerves.
“Each patient with CIDP has different treatment needs, and we have found that having one approved dosing option is not always optimal,” said Angela Lukin, Global President, Hospital Business Unit, Pfizer Inc, in a press release. “The approval of this new indication with additional dosing options helps address an unmet patient need by providing healthcare providers with the ability to choose an approved dose that’s right for patients.”
Read the full press release here.